Market Place
Sourcing Support
Immuneering Granted Orphan Drug Designation For IMM-1-104
15 Oct 2024 //
GLOBENEWSWIRE
Immuneering Reports Positive Phase 2a Data For IMM-1-104
12 Sep 2024 //
GLOBENEWSWIRE
Immuneering to Present at Morgan Stanley Global Healthcare Conference
29 Aug 2024 //
GLOBENEWSWIRE
Immuneering Reports Q2 2024 Results And Business Updates
06 Aug 2024 //
GLOBENEWSWIRE
Immuneering Gets FDA Fast Track For IMM-1-104 In Pancreatic Cancer
31 Jul 2024 //
GLOBENEWSWIRE
Immuneering to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Immuneering Recognizes Melanoma Awareness Month
06 May 2024 //
GLOBENEWSWIRE
Immuneering Q1 2024 Results and Business Update
06 May 2024 //
GLOBENEWSWIRE
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09 Apr 2024 //
GLOBENEWSWIRE
Immuneering to Participate in the 23rd Annual Needham Virtual Conference
03 Apr 2024 //
GLOBENEWSWIRE
Immuneering Announces First Dosed in its Phase 1/2a Trial to Treat Neoplasms
27 Mar 2024 //
GLOBENEWSWIRE
Immuneering Announces Positive Topline Results from Ph 1/2a Trial of IMM-1-104
14 Mar 2024 //
GLOBENEWSWIRE
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
12 Mar 2024 //
GLOBENEWSWIRE
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104
11 Mar 2024 //
GLOBENEWSWIRE
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104
05 Mar 2024 //
GLOBENEWSWIRE
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04 Mar 2024 //
GLOBENEWSWIRE
Immuneering Receives FDA Fast Track Designation for IMM-1-104
20 Feb 2024 //
GLOBENEWSWIRE
Immuneering Announces Participation in February Investor Conferences
01 Feb 2024 //
GLOBENEWSWIRE
Immuneering Announces FDA Clearance of IND for Phase 1/2a Trial of IMM-6-415
12 Dec 2023 //
GLOBENEWSWIRE
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
Immuneering Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Immuneering Presents Data Showing Encouraging Anti-Tumor Activity for IMM-1-104
12 Oct 2023 //
GLOBENEWSWIRE
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415
04 Oct 2023 //
GLOBENEWSWIRE
Immuneering to Present at the Morgan Stanley Healthcare Conference
06 Sep 2023 //
GLOBENEWSWIRE
Immuneering Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial
05 Jun 2023 //
GLOBENEWSWIRE
Immuneering to Present at the Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Immuneering Reports 1Q FYR 2023 and Provides Business Updates
04 May 2023 //
GLOBENEWSWIRE
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 Apr 2023 //
GLOBENEWSWIRE
Immuneering to Present Phase 1 Safety Data for Universal-RAS Program IMM-1-104
05 Apr 2023 //
GLOBENEWSWIRE
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
28 Mar 2023 //
GLOBENEWSWIRE
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at Meeting
14 Mar 2023 //
GLOBENEWSWIRE
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Immuneering Presents Preclinical Data with Lead Program IMM-1-104
05 Mar 2023 //
GLOBENEWSWIRE
Immuneering Announces Participation in March Investor Conferences
28 Feb 2023 //
GLOBENEWSWIRE
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Immuneering To Present at Guggenheim 2023 Oncology Conference
31 Jan 2023 //
GLOBENEWSWIRE
Immuneering Announces First Patient Dosed in Phase 1/2a Trial of IMM-1-104
28 Nov 2022 //
GLOBENEWSWIRE
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415
10 Nov 2022 //
GLOBENEWSWIRE
Immuneering Appoints Leah R. Neufeld as Chief People Officer
20 Oct 2022 //
GLOBENEWSWIRE
Immuneering To Present Poster on IMM-6-415 at the 37th (SITC)
05 Oct 2022 //
GLOBENEWSWIRE
FDA grants IND clearance for Immuneering’s Phase I/IIa solid tumour trial
03 Oct 2022 //
CLINICALTRIALSARENA
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a
30 Sep 2022 //
GLOBENEWSWIRE
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a
02 Sep 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in September Investor Conferences
25 Aug 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in William Blair Biotech Conference 2022
06 Jul 2022 //
GLOBENEWSWIRE
Immuneering Reports Data in Two PC Abstracts at the ASCO 2022 on IMM-1-104
26 May 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in Upcoming Investor Conferences
20 May 2022 //
GLOBENEWSWIRE
Immuneering Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day
05 May 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
01 Apr 2022 //
GLOBENEWSWIRE
Immuneering Announces Participation in the 21st Annual Needham Conference
24 Mar 2022 //
GLOBENEWSWIRE
Frazier Life Sciences Closes $987 M Venture Fund
15 Mar 2022 //
BUSINESSWIRE
Immuneering Announces Participation in March Investor Conferences
24 Feb 2022 //
GLOBENEWSWIRE
Immuneering Shows Compelling PC Data on IMM-1-104 in NRAS Mutant Melanoma Model
06 Jan 2022 //
GLOBENEWSWIRE
Immuneering Announces Inclusion in the Russell 2000® Index
20 Sep 2021 //
GLOBENEWSWIRE
Immuneering Reports Second Quarter 2021 Financial Results
09 Sep 2021 //
GLOBENEWSWIRE
Immuneering Announces Pricing of Upsized Initial Public Offering
29 Jul 2021 //
GLOBENEWSWIRE
